DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM

Inclusion Criteria: * Patients must be eligible to receive standard of care CAR T-cell therapy for relapsed or refractory multiple myeloma * Patients must be ≥18 years of age * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Patients must have 20% or more plasma cells in the bone marrow core or aspirate differential within 30 days prior to enrollment. * Patients must have adequate organ function as defined below: * Total bilirubin ≤ 1.5 x institutional upper limit of normal * AST ≤ 3 x institutional upper limit of normal * ALT ≤ 3 x institutional upper limit of normal * Creatinine clearance ≥ 40 mL/min for participants with creatinine levels above institutional normal * The effects of DC/MM fusion vaccine on the developing human fetus are unknown. For this reason, women and men of child-bearing potential must agree to use adequate contraception (hormonal or barrier methods of birth control or abstinence) prior to study enrollment and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner are participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of treatment. * Ability to understand and willingness to sign a written informed consent document. Exclusion Criteria: * Patients re…